Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial

Will the Biotech sector sustain its momentum in 2024?

Written by Ryan Hasson | Reviewed by Don Miller
January 4, 2024

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Upgrade below.

Upgrade Now See Benefits
→ Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad)

Should you invest $1,000 in iShares Biotechnology ETF right now?

Before you consider iShares Biotechnology ETF, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iShares Biotechnology ETF wasn't on the list.

While iShares Biotechnology ETF currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Amgen (AMGN)
4.5107 of 5 stars		$300.19-1.8%3.00%42.88Moderate Buy$305.65
Gilead Sciences (GILD)
4.9508 of 5 stars		$63.94-2.6%4.82%177.61Hold$83.69
Vertex Pharmaceuticals (VRTX)
3.9353 of 5 stars		$446.88-2.2%N/A29.00Moderate Buy$432.18
iShares Biotechnology ETF (IBB)N/A$134.08-1.2%0.31%N/AN/AN/A
Compare These Stocks  Add These Stocks to My Watchlist 

Ryan Hasson

About Ryan Hasson

  • Ry.has7@gmail.com

Contributing Author

Technical Analysis, Momentum Trading, Risk Management

Experience

Ryan Hasson has been a contributing writer for MarketBeat since 2023.

Areas of Expertise

Equity research and analysis, technical analysis and price action, market sentiment and underlying themes, risk management and trading psychology

Education

Bachelor of Commerce in Financial Management

Past Experience

Equities trader, Kershner Trading Group, business analysis consultant, SMB Capital

Zoom International: Business Analysis Consultant.

More From MarketBeat
WARNING about the death of the U.S. dollar…
from Colonial Metals
7 Best $5 Dollar Stocks to Buy
from MarketBeat
Digitizing the $11T commodities sector with one tiny stock
from Resource Stock Digest
7 Stocks That Don’t Need an AI Boost to Move Higher
from MarketBeat
Tim Sykes’ Urgent Trade Alert: “Make this move now”
from Timothy Sykes
7 Uranium Stocks That Can Fuel a Growth Portfolio in 2024
from MarketBeat
Biggest Prediction of My 50-Year Career on Wall Street
from Chaikin Analytics
7 Technology Stocks That Analysts Love The Most
from MarketBeat

Featured Articles and Offers

Recent Videos

4 of the Best Stocks for Share Buybacks
4 of the Best Stocks for Share Buybacks
Micron Stock is the NVIDIA of Memory
Micron Stock is the NVIDIA of Memory
NVIDIA’s Explosive Growth: Why the AI Leader’s Rally Isn’t Over Yet
NVIDIA’s Explosive Growth: Why the AI Leader’s Rally Isn’t Over Yet
4 Downgraded Stocks Still Worth a Look
4 Downgraded Stocks Still Worth a Look
Search Headlines: